MBTPS1 and COVID-19: To date, three S1P-based FDA-approved drugs, FTY720, Ozanimod, and Opaganib are being repurposed for COVID-19 treatment and are currently in clinical trials highlighting the potential for targeting the SphK-S1P-S1PRs to reduce COVID-19 symptoms.